1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models

類似資料

• 719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates
  著者:: Jia Chen, 等
  出版事項: (2021-11-01)
• 568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
  著者:: Wilson Guzman, 等
  出版事項: (2020-11-01)
• XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
  著者:: Zhen Liu, 等
  出版事項: (2023-12-01)
• 611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
  著者:: David Miller, 等
  出版事項: (2023-11-01)
• Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge
  著者:: Klara Totpal, 等
  出版事項: (2020-10-01)